The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus

Clinical Therapeutics

Volumn 25, Issue 5, 2003, Pages 1429-1439

  Derosa, Giuseppe ^a   Cicero, Arrigo F G ^b   Gaddi, Antonio ^b   Mugellini, Amedeo ^a   Ciccarelli, Leonardina ^a   Fogari, Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Hypercholesterolemia; L carnitine; Lipid profile; Lipoprotein(a); Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CARNITINE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN BLOOD LEVEL; ITALY; LABORATORY TEST; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PROTEIN GLYCOSYLATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037945488     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80130-3     Document Type: Article

References (37)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
2. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol. 1998;82:57-66.
3. Glader CA, Birgander LS, Stenlund H, Dahlen GH. Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med. 2002;252:27-35.
4. Peltier M, Iannetta Peltier MC, Sarano ME, et al. Elevated serum lipoprotein(a) level is an independent marker of severity of thoracic aortic atherosclerosis. Chest. 2002;1212:1589-1594.
5. Misirli H, Somay G, Ozbal N, Yasar Erenoglu N. Relation of lipid and lipoprotein(a) to ischaemic stroke. J Clin Neurosci. 2002;9:127-132.
6. Nawawi HM, Muhajir M, Kian YC, et al. Type of diabetes and waist-hip ratio are important determinants of serum lipoprotein(a) levels in diabetic patients. Diabetes Res Clin Pract. 2002;56:221-227.
7. Mace TH, Ahmadi R, Derfler K, et al. Influence of lipoprotein(a) on restenosis after femoropopliteal percutaneous transluminal angioplasty in Type 2 diabetic patients. Diabet Med. 2002;19:300-306.
8. Tarkun I, Cetinarslan B, Canturk Z. Lipoprotein(a) concentrations in patients with type 2 diabetes mellitus without cardiovascular disease: Relationship to metabolic parameters and diabetic complications. Nutr Metab Cardiovasc Dis. 2002;12:127-131.
9. Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem. 2002;48:1454-1459.
10. Soma MR, Osnago-Gadda I, Paoletti R, et al. The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med. 1993;153:1462-1468.
11. Sirtori CR, Calabresi L, Ferrara S, et al. L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc Dis. 2000;10:247-251.
12. Pan J, Van JT, Chan E, et al. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes. Metabolism. 2002;51:1120-1127.
13. American Diabetes Association: Screening for Diabetes (Position Statement). Diabetes Care. 2001;24(Suppl 1):S21-S24.
14. Proposed International Guidelines for Biomedical Research Involving Human Subjects. The Council for International Organisation of Medical Sciences. Geneva; 1982.
15. A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med. 1999;16:716-730.
16. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia. 1972;8:260-266.
17. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: Relevance to diabetes mellitus. Science. 1978;200:21-27.
18. Klose S, Borner K. Enzymatic determination of total cholesterol with the Greiner Selective Analyzer (GSA II) [in German]. J Clin Chem Clin Biochem. 1977;15:121-130.
19. Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bermeyer HU, ed. Methods of Enzymatic Analysis. 2nd English ed. New York: Academic Press; 1974:18-31.
20. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1353.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
22. Leblond L, Marcel YL. The amphipathic alpha-helical repeats of apolipoprotein A-I are responsible for binding of high density lipoproteins to HepG2 cells. J Biol Chem. 1991;266:6058-6067.
23. De Loof H, Rosseneu M, Yang CY, et al. Human apolipoprotein B: Analysis of internal repeats and homology with other apolipoproteins. J Lipid Res. 1987;28:1455-1465.
24. Scanu AM, Scandiani L. Lipoprotein(a): Structure, biology, and clinical relevance. Adv Intern Med. 1991;36:249-270.
25. Utermann G, Menzel HJ, Kraft HG, et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentration in plasma. J Clin Invest. 1987;80:458-465.
26. Diaz M, Lopez F, Hernandez F, Urbina JA. L-carnitine effects on chemical composition of plasma lipoproteins of rabbits fed with normal and high cholesterol diets. Lipids. 2000;35:627-632.
27. Golper TA, Wolfson M, Ahmad S, et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney Int. 1990;38:904-911.
28. Maebashi M, Kawamura N, Sato M, et al. Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinaemia. Lancet. 1978;2:805-807.
29. Elisaf M, Bairaktari E, Katopodis K, et al. Effect of L-carnitine supplementation on lipid parameters in hemodialysis patients. Am J Nephrol. 1998;18:416-421.
30. Vesela E, Racek J, Trefil L, et al. Effect of L-carnitine supplementation in hemodialysis patients. Nephron. 2001;88:218-223.
31. Gaw A, Hobbs HH. Molecular genetics of lipoprotein (a): New pieces to the puzzle. Curr Opin Lipidol. 1994;5:149-155.
32. Zysow BR, Kauser K, Lawn RM, Rubanyi GM. Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice. Arterioscler Thromb Vasc Biol. 1997;17:1741-1745.
33. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271-276.
34. Ramharack R, Spahr MA, Sekerke CS, et al. CI-1011 lowers lipoprotein(a) and plasma cholesterol concentrations in chow-fed cynomolgus monkeys. Atherosclerosis. 1998;136:79-87.
35. Tamamogullari N, Silig Y, Icagasioglu S, Atalay A. Carnitine deficiency in diabetes mellitus complications. J Diabetes Complications. 1999;13:251-253.
36. Malone JI, Schocken DD, Morrison AD, Gilbert-Barness E. Diabetic cardiomyopathy and carnitine deficiency. J Diabetes Complications. 1999;13:86-90.
37. Digiesi V, Cantini F, Bisi G, et al. L-carnitine adjuvant therapy in essential hypertension. Clin Ther. 1994;144:391-395.